{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:17:34Z","timestamp":1786997854153,"version":"build-2736575974"},"reference-count":85,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014538","name":"Lembaga Pengelola Dana Pendidikan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014538","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.vaccine.2026.128341","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T01:27:52Z","timestamp":1771550872000},"page":"128341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Active surveillance methods to identify adverse events of special interest (AESIs) following vaccination against pandemic diseases: A scoping review"],"prefix":"10.1016","volume":"77","author":[{"given":"Lukman Ade","family":"Chandra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhite Bayu","family":"Nugroho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarir At","family":"Thobari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo Luis","family":"Dimaguila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Buttery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.128341_bb0005","series-title":"Eradication of vaccine-preventable diseases. Annu Rev Public Health","volume":"20","author":"Hinman","year":"1999"},{"key":"10.1016\/j.vaccine.2026.128341_bb0010","series-title":"Statement of the WHO Global Advisory Committee on Vaccine Safety (GACVS) COVID-19 subcommittee on reports of Guillain-Barr\u00e9 Syndrome (GBS) following adenovirus vector COVID-19 vaccines","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.vaccine.2026.128341_bb0015","article-title":"Fatal guillain-barr\u00e9 syndrome after the national influenza immunization program","volume":"30","author":"Keenlyside RA, Schonberger LB, Bregman DJ, Bolyai JZS","year":"1980","journal-title":"Neurology"},{"key":"10.1016\/j.vaccine.2026.128341_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128341_bb0025","doi-asserted-by":"crossref","DOI":"10.2105\/AJPH.2008.143081","article-title":"What should an ideal vaccine postlicensure safety system be?","volume":"99","author":"Griffin","year":"2009","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2026.128341_bb0030","doi-asserted-by":"crossref","DOI":"10.1586\/14760584.2014.866895","article-title":"Active surveillance for adverse events following immunization","volume":"13","author":"Crawford","year":"2014","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128341_bb0035","doi-asserted-by":"crossref","DOI":"10.34133\/2021\/9851067","article-title":"Active vaccine safety surveillance: global trends and challenges in China","volume":"2021","author":"Liu","year":"2021","journal-title":"Health data Science"},{"key":"10.1016\/j.vaccine.2026.128341_bb0040","article-title":"Leveraging real-world data for safety signal detection and Risk Management in pre-and Post-Market Settings","volume":"5","author":"Gavin","year":"2026","journal-title":"Frontiers in Drug Safety and Regulation"},{"key":"10.1016\/j.vaccine.2026.128341_bb0045","article-title":"Vaccine adverse event Mining of Twitter Conversations: 2-phase classification study","volume":"10","author":"Habibabadi","year":"2022","journal-title":"JMIR Med Inform"},{"key":"10.1016\/j.vaccine.2026.128341_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/ebm.2025.10555","article-title":"Pharmacovigilance in the digital age: gaining insight from social media data","volume":"250","author":"Dong","year":"2025","journal-title":"Exp Biol Med"},{"key":"10.1016\/j.vaccine.2026.128341_bb0055","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1002\/sim.10095","article-title":"Online causal inference with application to near real-time post-market vaccine safety surveillance","volume":"43","author":"Luo","year":"2024","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2026.128341_bb0060","author":"World Bank"},{"key":"10.1016\/j.vaccine.2026.128341_bb0065","doi-asserted-by":"crossref","DOI":"10.1001\/jama.1980.03300500016019","article-title":"Guillain-Barr\u00e9 syndrome in recipients of a\/New Jersey influenza vaccine","volume":"243","author":"Marks","year":"1980","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128341_bb0070","doi-asserted-by":"crossref","DOI":"10.1093\/oxfordjournals.aje.a112795","article-title":"Guillain-barre syndrome following vaccination in the national influenza immunization program, United States, 1976-1977","volume":"110","author":"Schonberger","year":"1979","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2026.128341_bb0075","doi-asserted-by":"crossref","DOI":"10.34172\/jrhs.2020.24","article-title":"Geographical distribution of COVID-19 cases and deaths worldwide","volume":"20","author":"Poorolajal","year":"2020","journal-title":"J Res Health Sci"},{"key":"10.1016\/j.vaccine.2026.128341_bb0080","doi-asserted-by":"crossref","DOI":"10.1177\/20420986221118972","article-title":"Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge","volume":"13","author":"Rudolph","year":"2022","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.vaccine.2026.128341_bb0085","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1186\/s12889-024-20234-0","article-title":"Public and health care provider attitudes, understanding, and behaviors regarding emergency use authorizations: a scoping literature review","volume":"24","author":"Rains","year":"2024","journal-title":"BMC Public Health"},{"key":"10.1016\/j.vaccine.2026.128341_bb0090","doi-asserted-by":"crossref","DOI":"10.1186\/s12992-024-01017-z","article-title":"Which roads lead to access? A global landscape of six COVID-19 vaccine innovation models","volume":"20","author":"Alonso Ruiz","year":"2024","journal-title":"Glob Health"},{"key":"10.1016\/j.vaccine.2026.128341_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbiomolbio.2023.02.004","article-title":"An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines","volume":"178","author":"Bayani","year":"2023","journal-title":"Prog Biophys Mol Biol"},{"key":"10.1016\/j.vaccine.2026.128341_bb0100","article-title":"Systematic review of active safety surveillance of vaccines and medicines in low- and middle-income countries","author":"Stergachis","year":"2025","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2026.128341_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2016.07.045","article-title":"A global review of national influenza immunization policies: analysis of the 2014 WHO\/UNICEF joint reporting form on immunization","volume":"34","author":"Ortiz","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128341_bb0110","article-title":"Landscape review of active vaccine safety surveillance activities for COVID-19 vaccines globally","volume":"18","author":"PA","year":"2024","journal-title":"Vaccine X"},{"key":"10.1016\/j.vaccine.2026.128341_bb0115","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-014544","article-title":"Collaboration within the global vaccine safety surveillance ecosystem during the COVID- 19 pandemic: lessons learnt and key recommendations from the COVAX vaccine safety working group","volume":"9","author":"Chandler","year":"2024","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.vaccine.2026.128341_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2022.12.031","article-title":"The v-safe after vaccination health checker: active vaccine safety monitoring during CDC\u2019s COVID-19 pandemic response","volume":"41","author":"Myers","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128341_bb0125","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2022.3271","article-title":"Association of SARS-CoV-2 vaccination during pregnancy with pregnancy outcomes","volume":"327","author":"Magnus","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2026.128341_bb0130","doi-asserted-by":"crossref","DOI":"10.1108\/LHT-09-2019-0179","article-title":"Electronic health records for better health in the lower- and middle-income countries: a landscape study","volume":"38","author":"Kumar","year":"2020","journal-title":"Libr Hi Tech"},{"key":"10.1016\/j.vaccine.2026.128341_bb0135","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2018-001065","article-title":"Use of routinely collected electronic healthcare data for postlicensure vaccine safety signal detection: a systematic review","volume":"4","author":"Mesfin","year":"2019","journal-title":"BMJ Glob Health"},{"key":"10.1016\/j.vaccine.2026.128341_bb0140","doi-asserted-by":"crossref","DOI":"10.1093\/jamiaopen\/ooz035","article-title":"Heterogeneity introduced by EHR system implementation in a de-identified data resource from 100 non-affiliated organizations","volume":"2","author":"Glynn","year":"2019","journal-title":"JAMIA Open"},{"key":"10.1016\/j.vaccine.2026.128341_bb0145","doi-asserted-by":"crossref","DOI":"10.7326\/M21-2452","article-title":"Association of AZD1222 and BNT162b2 COVID-19 vaccination with thromboembolic and thrombocytopenic events in frontline personnel\u00a0:a retrospective cohort study","volume":"175","author":"Hviid","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.vaccine.2026.128341_bb0150","article-title":"Booster vaccination with SARS-CoV-2 mRNA vaccines and myocarditis risk in adolescents and young adults: a Nordic cohort study of 8.9 million residents","author":"Hviid","year":"2022","journal-title":"MedRxiv"},{"key":"10.1016\/j.vaccine.2026.128341_bb0155","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-063645","article-title":"Background rate estimations for thrombosis with thrombocytopaenia: challenges in evaluating rare safety signals following vaccination in real time during a pandemic","volume":"13","author":"M\u00fcllerov\u00e1","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.vaccine.2026.128341_bb0160","article-title":"Incidence of adverse events of special interest in the pre-COVID and active COVID era as historical comparators for postmarketing safety surveillance of SARS-COV-2 vaccines","volume":"31","author":"Mues","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2026.128341_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2021.12.143","article-title":"Prevalence of Covishield COVID-19 vaccine (ChAdOx1 nCoV-19) adverse effects among health care workers in Sri Lanka","volume":"116","author":"Manilgama","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128341_bb0170","doi-asserted-by":"crossref","DOI":"10.3390\/life11030249","article-title":"Self-reported real-world safety and reactogenicity of covid-19 vaccines: a vaccine recipient survey","volume":"11","author":"Mathioudakis","year":"2021","journal-title":"Life"},{"key":"10.1016\/j.vaccine.2026.128341_bb0175","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.17055","article-title":"Reporting at least one adverse effect post-COVID-19 vaccination from primary health Care in Muscat","author":"Al Ghafri","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.vaccine.2026.128341_bb0180","doi-asserted-by":"crossref","DOI":"10.1093\/qjmed\/hcad069.145","article-title":"Myocardial safety following COVID-19 vaccination","volume":"116","author":"Barsoum","year":"2023","journal-title":"QJM: An International Journal of Medicine"},{"key":"10.1016\/j.vaccine.2026.128341_bb0185","doi-asserted-by":"crossref","DOI":"10.1007\/s13760-023-02373-0","article-title":"Spectrum of various CNS inflammatory demyelination diseases following COVID-19 vaccinations","volume":"124","author":"Salunkhe","year":"2024","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.vaccine.2026.128341_bb0190","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2010-1722H","article-title":"The vaccine safety datalink: a model for monitoring immunization safety","volume":"127","author":"Baggs","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2026.128341_bb0195","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-47486-x","article-title":"Thrombocytopenia and venous thromboembolic events after BNT162b2, CoronaVac, ChAdOx1 vaccines and SARS-CoV-2 infection: a self-controlled case series study","volume":"13","author":"Ab Rahman","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128341_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2015.07.061","article-title":"Perinatal survival and health after maternal influenza a(H1N1)pdm09 vaccination: a cohort study of pregnancies stratified by trimester of vaccination","volume":"33","author":"Baum","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128341_bb0205","first-page":"2021","article-title":"Safety monitoring of multiple health outcomes following 2023\u20132024 COVID-19 vaccination among Medicare beneficiaries aged 65 years and older in the United States","author":"Gruber","year":"2025","journal-title":"MedRxiv"},{"key":"10.1016\/j.vaccine.2026.128341_bb0210","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.13512","article-title":"Use of immunization information systems in ascertainment of COVID-19 vaccinations for claims-based vaccine safety and effectiveness studies","volume":"6","author":"Schneider","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2026.128341_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2023.08.079","article-title":"Background rates of adverse events of special interest for COVID-19 vaccines: a multinational global vaccine data network (GVDN) analysis","volume":"41","author":"Phillips","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128341_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2022.09.2258","article-title":"RWD33 analysis of COVID-19 vaccine-related adverse events in adults, geriatrics and pediatrics \u2013 a retrospective study","volume":"25","author":"Roy","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2026.128341_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2023.04.041","article-title":"Background incidence rates of selected adverse events of special interest (AESI) to monitor the safety of COVID-19 vaccines","volume":"41","author":"Pillsbury","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128341_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2022.04.065","article-title":"Background incidence rates of adverse events of special interest related to COVID-19 vaccines in Ontario, Canada, 2015 to 2020, to inform COVID-19 vaccine safety surveillance","volume":"40","author":"Nasreen","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128341_bb0235","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1001\/jamapediatrics.2024.1917","article-title":"COVID-19 vaccination in the first trimester and major structural birth defects among live births","volume":"178","author":"Kharbanda","year":"2024","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.vaccine.2026.128341_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000441","article-title":"Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study","volume":"8","author":"Omer","year":"2011","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2026.128341_bb0245","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-30940-1","article-title":"Real-world data on the incidence and risk of Guillain\u2013Barr\u00e9 syndrome following SARS-CoV-2 vaccination: a prospective surveillance study","volume":"13","author":"Ha","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128341_bb0250","series-title":"The Brighton collaboration: Creating a global standard for case definitions (and guidelines) for adverse events following immunization","author":"Kohl","year":"2005"},{"key":"10.1016\/j.vaccine.2026.128341_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.amepre.2011.04.004","article-title":"H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project","volume":"41","author":"Lee","year":"2011","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.vaccine.2026.128341_bb0260","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2022-071594","article-title":"Comparative risk of thrombosis with thrombocytopenia syndrome or thromboembolic events associated with different covid-19 vaccines: international network cohort study from five European countries and the US","author":"Li","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128341_bb0265","doi-asserted-by":"crossref","DOI":"10.1093\/aje\/kwt078","article-title":"Safety of MF59-adjuvanted influenza vaccination in the elderly: results of a comparative study of mf59-adjuvanted vaccine versus nonadjuvanted influenza vaccine in northern Italy","volume":"178","author":"Villa","year":"2013","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2026.128341_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0082222","article-title":"Guillain-Barr\u00e9 syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: a multinational self-controlled case series in Europe","volume":"9","author":"Romio","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2026.128341_bb0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127441","article-title":"Lessons learnt during establishment of COVID-19 active vaccine safety surveillance in nine African countries","volume":"62","author":"Cutland","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128341_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2010.04.041","article-title":"Can the Brighton collaboration case definitions be used to improve the quality of adverse event following immunization (AEFI) reporting?. Anaphylaxis as a case study","volume":"28","author":"Gold","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128341_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.06.046","article-title":"Applicability of selected Brighton collaboration case definitions in low-resource settings: a prospective hospital-based active surveillance in Addis Ababa, Ethiopia","volume":"42","author":"Sintayehu","year":"2024","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128341_bb0290","article-title":"Maternal exposures to COVID-19 vaccine and adverse birth outcomes: National Population Study in Korea","volume":"40","author":"Kim","year":"2025","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.vaccine.2026.128341_bb0295","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa845","article-title":"Seasonal influenza vaccination during pregnancy and the risk of major congenital malformations in live-born infants: a 2010\u20132016 historical cohort study","volume":"73","author":"Peppa","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128341_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2012.05.1001","article-title":"Adverse events following immunization from pandemic influenza A (H1N1) - Laos 2010","volume":"16","author":"Lylianou","year":"2012","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128341_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2020.01.033","article-title":"Safety of influenza vaccination on adverse birth outcomes among pregnant women: a prospective cohort study in Japan","volume":"93","author":"Ohfuji","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.vaccine.2026.128341_bb0310","doi-asserted-by":"crossref","DOI":"10.1620\/tjem.2023.J002","article-title":"Acute adverse events at a mass vaccination site after the third and fourth COVID-19 vaccinations in Japan","volume":"259","author":"Akaishi","year":"2023","journal-title":"Tohoku J Exp Med"},{"key":"10.1016\/j.vaccine.2026.128341_bb0315","article-title":"Maternal and perinatal outcomes of COVID-19 vaccination during pregnancy","volume":"24","author":"S\u00fct","year":"2023","journal-title":"J Turk-Ger Gynecol Assoc"},{"key":"10.1016\/j.vaccine.2026.128341_bb0320","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2021.2828","article-title":"Patients with acute myocarditis following mrna covid-19 vaccination","volume":"6","author":"Kim","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.vaccine.2026.128341_bb0325","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-021-01324-5","article-title":"Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis","volume":"22","author":"Garc\u00eda-Azor\u00edn","year":"2021","journal-title":"J Headache Pain"},{"key":"10.1016\/j.vaccine.2026.128341_bb0330","doi-asserted-by":"crossref","DOI":"10.2196\/58991","article-title":"A texting-and internet-based self-reporting system for enhanced vaccine safety surveillance with insights from a large integrated health care system in the United States: prospective cohort study","volume":"12","author":"Malden","year":"2024","journal-title":"JMIR Mhealth Uhealth"},{"key":"10.1016\/j.vaccine.2026.128341_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2021.06.006","article-title":"Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines","volume":"2","author":"McMurry","year":"2021","journal-title":"Med"},{"key":"10.1016\/j.vaccine.2026.128341_bb0340","series-title":"Web and social media listening using AI\/NLP for COVID-19 vaccine safety monitoring. Pharmacoepidemiol. Drug Saf., vol. 31, WILEY 111 RIVER ST, HOBOKEN 07030\u20135774, NJ USA","first-page":"124","author":"Khromava","year":"2022"},{"key":"10.1016\/j.vaccine.2026.128341_bb0345","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-151396","article-title":"Deep vein thrombosis after COVID-19 vaccinations","volume":"138","author":"Houghton","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.vaccine.2026.128341_bb0350","doi-asserted-by":"crossref","DOI":"10.2196\/53424","article-title":"Application of a language model tool for COVID-19 vaccine adverse event monitoring using web and social media content: algorithm development and validation study","volume":"4","author":"Daluwatte","year":"2024","journal-title":"JMIR Infodemiol"},{"key":"10.1016\/j.vaccine.2026.128341_bb0355","doi-asserted-by":"crossref","unstructured":"Hatmal MM, Al-Hatamleh MAI, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, et al. Side effects and perceptions following covid-19 vaccination in Jordan: a randomized, cross-sectional study implementing machine learning for predicting severity of side effects. Vaccines (Basel) 2021;9. Doi: https:\/\/doi.org\/10.3390\/vaccines9060556.","DOI":"10.3390\/vaccines9060556"},{"key":"10.1016\/j.vaccine.2026.128341_bb0360","article-title":"Machine learning approach for active vaccine safety monitoring","volume":"36","author":"Kim","year":"2021","journal-title":"J Korean Med Sci"},{"key":"10.1016\/j.vaccine.2026.128341_bb0365","article-title":"Artificial intelligence models predicting abnormal uterine bleeding after COVID-19 vaccination","volume":"15","author":"Choi","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2026.128341_bb0370","doi-asserted-by":"crossref","DOI":"10.1017\/S0950268811001531","article-title":"Use of the self-controlled case-series method in vaccine safety studies: review and recommendations for best practice","volume":"139","author":"Weldeselassie","year":"2011","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.vaccine.2026.128341_bb0375","doi-asserted-by":"crossref","DOI":"10.2307\/2533328","article-title":"Relative incidence estimation from case series for vaccine safety evaluation","volume":"51","author":"Farrington","year":"1995","journal-title":"Biometrics"},{"key":"10.1016\/j.vaccine.2026.128341_bb0380","doi-asserted-by":"crossref","DOI":"10.1097\/INF.0b013e3181d581f9","article-title":"Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization","volume":"29","author":"Klein","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2026.128341_bb0385","doi-asserted-by":"crossref","DOI":"10.1002\/pds.3638","article-title":"Risk of Guillain-Barr\u00e9 syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany","volume":"23","author":"Prestel","year":"2014","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2026.128341_bb0390","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehad339","article-title":"COVID-19 vaccination-related myocarditis: a Korean nationwide study","volume":"44","author":"Cho","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.vaccine.2026.128341_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/ph18010080","article-title":"Real-time pharmacovigilance: transforming population-based monitoring of post-approval vaccine safety through rapid cycle analysis (RCA)\u2014a review of the published literature","volume":"18","author":"Gandhi","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.vaccine.2026.128341_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2025.127044","article-title":"A rapid cycle analytics framework for vaccine safety surveillance within a real-world data network: experience with enhanced surveillance of the Janssen COVID-19 vaccine","volume":"55","author":"Newbern","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128341_bb0405","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2023-061894","article-title":"Safety of COVID-19 mRNA vaccination among young children in the vaccine safety datalink","volume":"152","author":"Goddard","year":"2023","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2026.128341_bb0410","doi-asserted-by":"crossref","DOI":"10.1002\/pds.3918","article-title":"Pharmacoepidemiological considerations in observed-to-expected analyses for vaccines","volume":"25","author":"Mahaux","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2026.128341_bb0415","article-title":"Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2026.128341_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2022.11.069","article-title":"Surveillance of COVID-19 vaccine safety among elderly persons aged 65 years and older","volume":"41","author":"Wong","year":"2023","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128341_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.01.100","article-title":"COVID-19 vaccines and adverse events of special interest: a multinational global vaccine data network (GVDN) cohort study of 99 million vaccinated individuals","volume":"42","author":"Faksova","year":"2024","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26001490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26001490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T06:25:25Z","timestamp":1776147925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26001490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":85,"alternative-id":["S0264410X26001490"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128341","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Active surveillance methods to identify adverse events of special interest (AESIs) following vaccination against pandemic diseases: A scoping review","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128341","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128341"}}